(Q30362811)

20 June 2017

title

Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms. (English)

1 reference

20 June 2017

0 references

1 reference

Kanta Subbarao

2

0 references

author name string

Catherine J Luke

series ordinal

1

1 reference

20 June 2017

publication date

23 May 2014

1 reference

Expert Review of Vaccines

20 June 2017

published in

1 reference

20 June 2017

volume

13

1 reference

20 June 2017

issue

7

1 reference

20 June 2017

page(s)

873-883

1 reference

An overlapping protein-coding region in influenza A virus segment 3 modulates the host response

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

A distinct lineage of influenza A virus from bats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

New world bats harbor diverse influenza A viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Past, present, and possible future human infection with influenza virus A subtype H7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

H5N1 influenza viruses: outbreaks and biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Influenza viruses: from birds to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Avian influenza viruses infecting humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

21 January 2018

Influenza vaccine—live

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Influence of prior influenza vaccination on antibody and B-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

The prospects and challenges of universal vaccines for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

21 January 2018

H5N1 vaccines in humans

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Vaccines for pandemic influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Scientific barriers to developing vaccines against avian influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Update on avian influenza A (H5N1) virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Prime-boost approaches to tuberculosis vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Prime-boost vectored malaria vaccines: progress and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2014.922416

10.1586/14760584.2014.922416

21 January 2018

Identifiers

DOI

1 reference

20 June 2017

1 reference